Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

20.73 -9.32 (-31.01%)
Official Closing Price Updated: 4:15 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
These stocks are moving in today's session
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes. 
Via Chartmill
Here are the top movers in Thursday's session.
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Earnings Scheduled For October 30, 2025
 
Via Benzinga
Apellis Short Bets Edge Higher As Stock Jumps 45% Since Late July Q2 Report — Retail Traders Stay Wary
Via Stocktwits
Earnings Scheduled For July 31, 2025
 
Via Benzinga
Earnings Scheduled For May 7, 2025
 
Via Benzinga
Apellis Pharmaceuticals's Earnings Outlook
 
Via Benzinga
Breaking Down Apellis Pharmaceuticals: 6 Analysts Share Their Views
 
Via Benzinga
The market is filled with gapping stocks in Thursday's session.
Today's session on Thursday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
Apellis Pharmaceuticals Inc (NASDAQ:APLS) Reports Strong Q3 2025 Earnings Beat
Apellis Pharmaceuticals (APLS) Q3 2025 earnings crushed estimates, driven by strong drug sales and a major partnership payment. The company achieved profitability and positive market reaction. 
Via Chartmill
Insights Ahead: Apellis Pharmaceuticals's Quarterly Earnings
 
Via Benzinga
Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 11 Analysts
 
Via Benzinga
12 Analysts Assess Apellis Pharmaceuticals: What You Need To Know
During the last three months, 12 analysts shared their evaluations of Apellis Pharmaceuticals (NASDAQ: APLS), revealing diverse outlooks from bullish to bearish. The table below summarizes their recent... 
Via Benzinga
Concentrix Posts Downbeat Earnings, Joins Legacy Education, Kingsoft Cloud And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Friday. 
Via Benzinga
Topics Stocks
Why Top KingWin Shares Are Trading Higher By 87%; Here Are 20 Stocks Moving Premarket
Shares of Top KingWin Ltd (NASDAQ: WAI) rose sharply in pre-market trading after the company announced it entered into a sales contract with Walker Times International for the sale of 10,000 units of... 
Via Benzinga
Topics Artificial Intelligence
Retail Buzz Surges For Apellis As Goldman Hikes Price Target After Solid Syfovre Sales, FDA Win For Kidney Drug
Goldman Sachs cited Apellis’ 6% quarterly injection growth for Syfovre and potential market upside from Empaveli’s newly approved indications in C3G and IC-MPGN, despite recent revenue headwinds from... 
Via Stocktwits
Roblox, Carvana, eBay, C.H. Robinson Worldwide, Huntington Ingalls Industries And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
APELLIS PHARMACEUTICALS INC (NASDAQ:APLS) Reports Mixed Q2 2025 Results with EPS Beat and Revenue Miss
Apellis Pharmaceuticals (APLS) reported mixed Q2 2025 results, missing revenue estimates ($178.49M vs. $192.29M) but beating EPS (-$0.33 vs. -$0.49). Shares rose 4.58% pre-market as FDA approval for... 
Via Chartmill
FDA Approval For Empaveli Marks Key Milestone In Apellis' Rare Disease Portfolio
FDA approves Apellis' Empaveli for rare kidney diseases, with trial data showing strong efficacy in reducing proteinuria and clearing C3 deposits. 
Via Benzinga
Why Retail Investors Are Turning Sharply Bullish On Apellis Pharmaceuticals
The FDA approved Apellis’ drug Empaveli for two rare kidney diseases, following strong results from a Phase 3 trial. 
Via Stocktwits
Apellis Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (15 Ratings)
 
Via Benzinga
What 13 Analyst Ratings Have To Say About Apellis Pharmaceuticals
 
Via Benzinga
Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 17 Analysts
 
Via Benzinga
Why Apellis Pharmaceuticals Wilted on Wednesday
Via The Motley Fool
Topics Earnings
Sarepta Therapeutics, Mercury Systems, Arista Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
What 9 Analyst Ratings Have To Say About Apellis Pharmaceuticals
 
Via Benzinga
FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals
Apellis' Empaveli receives FDA Priority Review for rare kidney diseases C3G and IC-MPGN. Phase 3 data show strong efficacy in proteinuria reduction. 
Via Benzinga
JP Morgan Cut Apellis' Price Forecasts, Cites Longer Peak Sales Timing For Syfovre
JP Morgan sees steady growth for Apellis' Syfovre, lowering the price target to $45. Syfovre sales hit $167.8M in Q4, with over 94,000 doses delivered. 
Via Benzinga
Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst
JP Morgan sees Apellis' Syfovre as a potential $1.5B drug. Empaveli's approval for C3G/IC-MPGN could drive stock growth with a U.S. launch in 2H 2025. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.